Carfilzomib Enhances Iodine-125-Induced Multi-Modal Cell Death in ESCC

Study Background and Research Question

Esophageal squamous cell carcinoma (ESCC) remains a major global health challenge, accounting for approximately 90% of esophageal cancer cases worldwide. Despite advances in systemic therapies, including chemotherapy, immunotherapy, and radiation, a significant proportion of patients present with locally advanced or metastatic disease. Iodine-125 (125I) seed continuous low-dose-rate (CLDR) brachytherapy is a clinically established modality for controlling tumor recurrence and alleviating malignant dysphagia in ESCC. However, the efficacy of 125I seed brachytherapy is often compromised by the emergence of radioresistance, underlining the need for effective radiosensitization strategies. One of the pivotal mechanisms underlying 125I-induced tumor cell death is endoplasmic reticulum stress (ERS) and the subsequent unfolded protein response (UPR). The present study addresses whether aggravating ERS using a potent proteasome inhibitor, Carfilzomib (PR-171), can potentiate the antitumor effects of 125I seed radiation in ESCC by promoting multiple forms of cell death.

Key Innovation from the Reference Study

The central innovation of the referenced work (Wang et al., 2025) is the demonstration that Carfilzomib, an irreversible proteasome inhibitor, significantly enhances the cytotoxic effect of 125I seed radiation in ESCC. Unlike previous approaches that focused primarily on apoptosis, this study elucidates how the combination therapy simultaneously induces apoptosis, paraptosis, and ferroptosis through aggravated ERS and modulation of UPR pathways. The research reveals a previously uncharacterized synergy wherein proteasome inhibition disrupts protein homeostasis, amplifies ERS, and expands the cell death repertoire beyond canonical apoptosis. Importantly, the study delineates the involvement of the UPR-C/EBP homologous protein (CHOP) axis and highlights mechanisms that are both p53-dependent and independent, offering nuanced mechanistic insights for radiosensitization.

Methods and Experimental Design Insights

The researchers employed both in vitro and in vivo approaches to dissect the combinatorial effects of Carfilzomib and 125I seed radiation:

• ESCC cell lines were treated with Carfilzomib alone, 125I seed radiation alone, or their combination.
• Cell death modalities were assessed by flow cytometry, immunoblotting, and morphological analysis.
• Markers of ERS (e.g., BiP/GRP78, CHOP), UPR pathway activation, and proteasome activity were quantified.
• Reactive oxygen species (ROS), DNA damage, mitochondrial pathway activation, intracellular Ca²⁺ levels, and protein ubiquitination were measured to map downstream effects.
• Ferroptosis was evaluated by monitoring Fe²⁺ accumulation, lipid peroxidation, and expression levels of ferroptosis inhibitors SLC7A11 and GPX4.
• In vivo efficacy and tolerability of the combination therapy were validated using mouse xenograft models of ESCC.

This comprehensive design enabled the delineation of both mechanistic pathways and translational potential.

Protocol Parameters

• Carfilzomib dosing: In vivo, up to 5 mg/kg weekly via intravenous injection was tolerated, as indicated by the product information and in alignment with mouse xenograft protocols in the reference study.
• Combination treatment timing: Carfilzomib was administered prior to, or concurrently with, 125I seed placement to maximize radiosensitization.
• ERS and UPR marker assessment: Quantify BiP/GRP78, CHOP, and ubiquitinated proteins within 24–48 hours post-treatment for mechanistic validation.
• Ferroptosis monitoring: Assess intracellular Fe²⁺, lipid ROS, and GPX4 expression to confirm ferroptosis induction.
• Solution preparation: Carfilzomib is best dissolved in DMSO at ≥35.99 mg/mL and should be freshly prepared and stored below -20°C for short-term use, as per the manufacturer's guidance.

Core Findings and Why They Matter

According to the reference study, the combination of Carfilzomib and 125I seed radiation in ESCC models produces a robust and multi-modal cytotoxic response:

• Enhanced Apoptosis: 125I seed radiation induces ROS, DNA damage, p53 activation, and mitochondrial apoptosis. Carfilzomib augments these effects via the UPR-CHOP pathway, even in a p53-independent manner, suggesting a broader applicability across p53 mutant tumors.
• Induction of Paraptosis: Carfilzomib significantly increases ERS, intracellular Ca²⁺ overload, and protein ubiquitination, leading to ER swelling and the formation of paraptotic vacuoles. This non-canonical cell death pathway may offer an avenue to overcome resistance to apoptosis.
• Promotion of Ferroptosis: Although 125I seed radiation increases intracellular Fe²⁺ and lipid peroxides, it also upregulates ferroptosis inhibitors SLC7A11 and GPX4. Carfilzomib counters this adaptive response by downregulating GPX4, thereby facilitating ferroptosis.
• In Vivo Validation: In mouse xenograft models, the combination therapy resulted in improved tumor control with good tolerability, supporting translational feasibility.

These findings collectively propose that targeting proteasome-mediated proteolysis and aggravating ERS can sensitize ESCC cells to radiation via multiple, interrelated cell death mechanisms. This strategy addresses both intrinsic and acquired radioresistance, expanding the therapeutic toolkit for ESCC.

Comparison with Existing Internal Articles

Several recent internal resources contextualize and reinforce the significance of Carfilzomib’s mechanistic profile:

• Mechanistic Leverage and Strategic Guidance highlights Carfilzomib's unique role in enabling multi-modal cell death and enhancing radiosensitivity, themes experimentally validated in the reference study. The internal guide further discusses strategic workflow integration for translational research.
• Optimizing Proteasome Inhibition Workflows provides practical protocols for maximizing proteasome inhibition and apoptosis induction in cancer research, echoing the importance of timing and dosing when combining Carfilzomib with other modalities such as radiation.
• Solving Lab Challenges with Carfilzomib (PR-171) details reproducibility in proteasome inhibition assays and offers troubleshooting for cell viability workflows, complementing the reference study's methodological rigor.

Collectively, these resources emphasize Carfilzomib's established and emerging utility in research focused on proteasome inhibition in cancer, and provide additional perspectives for protocol optimization.

Limitations and Transferability

While the reference study provides strong preclinical evidence, several limitations merit consideration:

• Findings are based on ESCC cell lines and mouse xenograft models; transferability to other tumor types or clinical settings requires further validation.
• The interplay between ERS, UPR, and cell death pathways may differ in more heterogeneous tumor microenvironments.
• Potential off-target or systemic effects of heightened ERS and multi-modal cell death induction were not fully explored in long-term in vivo settings.
• Optimal dosing schedules for maximal radiosensitization with minimal toxicity remain to be standardized for translational applications.

Despite these caveats, the mechanistic framework established by the study provides a strong rationale for further investigation and protocol refinement.

Research Support Resources

Researchers seeking to replicate or extend these findings in proteasome inhibition in cancer research can use Carfilzomib (PR-171) (SKU A1933), a highly potent, irreversible proteasome inhibitor validated in both in vitro and in vivo settings. For detailed workflow strategies, protocol troubleshooting, and mechanistic discussions relevant to apoptosis induction via proteasome inhibition and multi-modal cell death assays, consult the internal articles cited above. Carfilzomib (PR-171) is supplied by APExBIO for research use only and should be handled in accordance with best laboratory practices to ensure reproducibility and data integrity.